Introduction:
Ventricular tachycardia (VT) commonly develops in patients with
structural heart disease, especially those with myocardial scar, such as
prior myocardial infarction. [1,2] Catheter ablation has been found
to reduce incidence of VT storm, cardiovascular disease related
hospitalization, and implanted cardioverter defibrillator (ICD) shocks
when compared to medical therapy alone in patients with ischemic
cardiomyopathy and structural heart disease. [3, 4]
Adverse events related to VT ablation include tamponade, stroke, and
acute myocardial infarction. [5] chronic kidney disease (CKD) is
associated with an increased incidence of adverse events in
cardiovascular procedures such as percutaneous coronary interventions
[6]. The aim of our study is to evaluate the impact of CKD on
in-hospital mortality and clinical outcomes of VT ablation.